CFTR and chronic obstructive pulmonary disease: To verify prior studies in airway monolayers and tissues that implicated CFTR activation as a mechanism mediating the clinical benefit of roflumilast [20], we evaluated whether roflumilast alters CFTR function on the surface of the respiratory epithelium in healthy, wild-type mice, the anticipated CFTR genotype in the majority of COPD patients [23].